Deadline Passed Grant

MRC CBRN Medical Countermeasures R&D 2026–2027: Up to £4 Million for UK Research Projects

The MRC and DHSC are offering up to £4 million per project for UK-led pre-clinical and early translational medical countermeasure research, with a mandatory expression of interest due 20 October 2026.

FindMyMoney.App
Published by FindMyMoney.App
Official source: Medical Research Council (MRC), with the Department of Health and Social Care (DHSC)
💰 Funding Up to £4,000,000 per application; £20,000,000 total fund
📅 Historical deadline Oct 20, 2026
📍 Location United Kingdom
🏛️ Source Medical Research Council (MRC), with the Department of Health and Social Care (DHSC)

This captured cycle appears closed. Use this page for historical guidance unless the official source has reopened the program.

Captured cycle: This page is retained for historical guidance. Confirm whether the program has reopened before planning an application.

MRC CBRN Medical Countermeasures R&D 2026–2027: Up to £4 Million for UK Research Projects

The Medical Research Council (MRC), with co-funding from the Department of Health and Social Care (DHSC), has opened a 2026–2027 grant opportunity for UK research teams developing medical countermeasures for chemical, biological, radiological and nuclear (CBRN) threats. The call supports work from early prototype development through pre-clinical testing and refinement to early-phase clinical studies up to phase 2a. The central test is practical: the research should generate evidence that can improve domestic preparedness for CBRN incidents, particularly preparedness across the health system.

The call has a total fund of £20 million, with a maximum full economic cost (FEC) of £4 million per application. MRC funds 80% of FEC. An expression of interest (EOI) is mandatory and must arrive by 20 October 2026 at 4:00pm UK time. The EOI is a required first gate; it is not the full grant proposal. Only invited applicants will be able to submit the full application, which is scheduled to open on 5 November 2026 and close on 20 January 2027.

Key details

DetailInformation
OpportunityExpression of interest: Chemical, biological, radiological and nuclear (CBRN) medical countermeasures R&D
FunderMedical Research Council (MRC), with the Department of Health and Social Care (DHSC)
SupportResearch grant for pre-clinical and early translational medical countermeasure work
Total fund£20 million
Maximum request£4 million full economic cost per application; MRC funds 80% FEC
Project durationUp to 30 months
Current application stageMandatory EOI, followed by an invitation-only full application
EOI deadline20 October 2026, 4:00pm UK time
Full application window5 November 2026 to 20 January 2027, 4:00pm UK time, for invitees
Decision meeting14 April 2027
Lead eligibilityEmployed by a UK-based eligible research organisation and actively directing the project
Official sourceUKRI funding opportunity page

What the call is designed to support

This is a development-focused research call. Projects may work on medical countermeasures (MCMs) at different points in a pathway, but they need to connect the proposed research to an intervention and a preparedness need. The official scope includes novel vaccines, diagnostics and therapeutics; broad-spectrum interventions; symptomatic management approaches; and studies that assess whether existing medicines could be repurposed for CBRN threats.

The call names several priority areas: broad-spectrum countermeasures for shared symptoms or toxidromes; repurposing licensed medicines that might be held in hospitals or pharmacies; new vaccines, therapeutics and diagnostics for priority pathogens; and improved diagnostic or detection capability for radiological and nuclear incidents. These are priorities, not a requirement that every proposal address multiple threat types. A focused application can be easier to assess when it defines one preparedness problem, the intervention that could address it and the evidence needed to decide what should happen next.

The programme does not support fundamental or investigative research without a development plan. It also excludes studies whose main aim is simply to investigate disease mechanisms, technology development disconnected from a medical or clinical pathway, studies of physiological response without a countermeasure focus, and observational work with no experimental challenge. Applicants should explain the use case early so that a technically interesting project is not mistaken for a poor fit.

Who should consider applying

The lead applicant must be employed by a UK-based research organisation that is eligible for MRC funding. The person must direct the project and take an active role in its work. The call permits more than one research organisation to participate. A host institution may lead or partner on multiple proposals, but an individual may lead only one application. An individual can still be a co-lead on other applications.

This structure is aimed at academic-led teams with a credible route to deliver translational research. UK industry partners are encouraged when they add value, for example through expertise, technology, reagents, funding or access to sites and facilities. Collaboration is optional, however, and the application must make clear why the work is academic-led and why MRC support is needed. UK businesses and charities that are not eligible independent research organisations may participate as partners, but cannot lead or co-lead. International research and commercial organisations cannot take part as project lead, co-lead or project partner under this call.

For applicants without an employment contract covering the proposed project, the host organisation must confirm that it will extend the contract beyond the project end date if funded. It must also confirm that it will provide the support needed to deliver the project, including mentorship and career development for early-career researchers. This is worth resolving with the research office before the EOI, rather than treating it as a detail to settle after a funding decision.

What the award can pay for

The maximum request is £4 million FEC, and MRC will contribute 80% of FEC. Build the budget with the host research office because the award calculation follows full economic costing rules. The official list of potentially eligible costs includes a contribution to project lead and co-lead salaries, research and technical staff, consumables, equipment, travel, data preservation and sharing, dissemination, estates and indirect costs. Public partnership work and payments to public contributors can also be included when they are relevant to the research.

The grant does not fund PhD studentships, publication charges, bridge funding between grants or costs associated with applying for intellectual-property protection such as patent filing. Do not assume that an item is eligible simply because it appears in an earlier related award budget. Tie each cost to a defined activity, explain why the project needs it, and ask the research office to check treatment under the applicable FEC rules.

There is no requirement for institutional matched funding. Reviewers and panels must not use the level of institutional matched funding as a recommendation factor. The host must still provide the research environment and infrastructure needed for the funded work. Direct or in-kind contributions from partners are encouraged when they strengthen delivery, but they should not be presented as compulsory co-funding.

How to approach the mandatory expression of interest

The first step is to submit the CBRN EOI survey linked from the official opportunity page by 20 October 2026 at 4:00pm UK time. The EOI is mandatory. UKRI says the information will not be formally assessed; it will be used to check remit and fit, anticipate application volume, and inform peer-review and panel composition. If demand is high, MRC reserves the right to shortlist at this stage. That means an EOI should be accurate and sufficiently clear to establish fit even though it is not a full proposal.

Before filling in the survey, agree the core project description with the team and the research office. Be ready to state the CBRN preparedness gap, the proposed countermeasure, the developmental stage, the evidence the work will produce, and why that evidence matters to UK domestic preparedness. Avoid claims that the project will solve a broad national threat problem unless the proposed scope and outputs substantiate that claim. If there are likely industry partners, identify the role they may play and the capability they contribute.

The opportunity page currently identifies the EOI survey as the submission route. It does not publish the complete full application questions or assessment criteria yet. Do not invent an EOI word limit, mandatory attachment list or scoring scheme from another MRC call. Keep a record of what was submitted and verify any updates on UKRI’s page as the full-application window approaches.

Preparing for an invited full application

The full application is expected to run on the UKRI Funding Service, not Je-S. The UKRI page says the full stage opens on 5 November 2026 and closes on 20 January 2027 at 4:00pm UK time. Your institution should be registered with the Funding Service, and its research office should know that an invitation may follow. The full guidance will be published when that stage opens; those instructions will control the final question set, attachments and assessment criteria.

In the meantime, prepare a coherent project plan rather than drafting against assumed form fields. Define the target population or operational setting, the preparedness problem, the intervention, the stage of development and the decision that the proposed evidence will enable. Show how activities fit within the maximum 30-month duration. Projects should start one to six months after the funding decision date, so the schedule should account for approvals, site readiness, procurement and collaboration agreements without promising an unrealistic immediate start.

A useful preparation file can hold the project rationale, work packages, milestones, risk register, team responsibilities, partner contributions, data-management plan, and an outline budget. Clearly distinguish what the grant would support from work funded elsewhere. If the project depends on access to samples, facilities, data or clinical sites, establish that access early and identify a responsible contact. These are sound planning steps; the official page has not yet listed a definitive full-stage document checklist.

Build a convincing preparedness case

The clearest proposals connect three things: a defined threat or clinical preparedness gap, a countermeasure that could plausibly address it, and evidence that would make a concrete decision possible. State what is not currently known or available, why that matters to preparedness, and how the proposed research will reduce that uncertainty. Describe the intended use of results in terms of health-system readiness rather than relying only on the novelty of a technology.

For each objective, explain the development stage and a credible next step. If the project is early, identify what would count as a useful prototype or pre-clinical result and what finding would justify further development. If it extends toward early-phase clinical work, explain the relevant approvals and delivery arrangements at a suitable level for the application. Keep endpoints and milestones proportional to the 30-month limit and the budget.

The page does not yet disclose the full-stage scoring criteria, so applicants should not treat any unofficial formula as authoritative. Nonetheless, a proposal is easier for reviewers to assess when its rationale, methods, team capability, delivery plan, risks, data handling and public-health relevance fit together. Match each claim to evidence: prior results, access confirmations, partner statements, or a clear plan to generate evidence during the award. Avoid unsupported promises of direct emergency deployment if the proposed studies only establish earlier-stage evidence.

Plan partnerships and responsibilities

A collaboration is not required. Add partners where they close a real delivery gap: specialized expertise, equipment, reagents, facilities, data, sites, samples, participant recruitment or cash and in-kind support. The official page says each project partner must provide a statement of support. Where an industry partner falls within the industry collaboration framework, additional information may be required. Partner statements should specify the contribution and its timing, not simply praise the project.

Check role boundaries while assembling the team. A person listed in the core team cannot also be a project partner, and an organisation that employs a core-team member cannot be listed as a project partner organisation. People from the same organisation who contribute to the research may fit as co-leads or specialists instead. Ask the host grants office to review the structure early, because a role error can create avoidable eligibility or submission problems.

International collaboration brings UKRI Trusted Research and Innovation responsibilities. The call page says applicants may be asked to describe risks and proportionate controls. International organisations are not eligible as project leads, co-leads or partners under this opportunity, so check the relevant roles carefully before including an overseas entity. Consult the host institution’s due-diligence and research-security processes instead of relying on a generic statement that a collaboration is low risk.

Timeline and submission checkpoints

The EOI opened on 10 September 2026 and closes on 20 October 2026 at 4:00pm UK time. The invited full application stage is scheduled to open on 5 November 2026 at 9:00am and close on 20 January 2027 at 4:00pm. The funding decision meeting is scheduled for 14 April 2027. UKRI expects to inform applicants within 10 working days of that meeting. A funded project should start one to six months after the decision date.

Work backward from the EOI deadline and allow for internal approval. Confirm that the lead organisation is eligible; reserve time for the PI, finance lead and any partners to agree the project summary; and the captured-cycle instructions asked applicants to submit before the final day if possible. Keep the full-stage dates in the team calendar, but remember that the full application is invitation-only. A submitted EOI by itself does not guarantee an invitation or an award.

Common mistakes to avoid

  • Treating the EOI as optional or assuming that the full application can be submitted without an invitation.
  • Missing the 20 October EOI cut-off while waiting for the full application guidance.
  • Proposing basic science without a development plan or a defined medical countermeasure.
  • Describing CBRN relevance in general terms without explaining how the evidence improves domestic or health-system preparedness.
  • Having an ineligible lead, co-lead or partner role, especially for an international organisation, business or non-independent research charity.
  • Letting one person lead multiple applications when the rules allow an individual to lead only one.
  • Requesting costs excluded by the call, such as PhD studentships, publication charges, bridge funding or patent filing.
  • Building an over-ambitious work plan that does not fit the maximum 30 months or the stated start window.
  • Assuming that partner participation or matched funding is compulsory; neither is a prerequisite.
  • Relying on unconfirmed assumptions about full-stage assessment criteria or attachments instead of checking the Funding Service guidance when it is published.

Frequently asked questions

Is the £4 million maximum the amount MRC pays?

The page describes the maximum as £4 million FEC per application and says MRC funds 80% FEC. Prepare the project cost using the host institution’s FEC process; do not interpret the cap as a guaranteed cash award.

Can an international university lead or partner?

No. An international research or commercial organisation cannot participate as project lead, co-lead or project partner under this opportunity. UK-based eligible research organisations must lead the application.

Can a business or charity apply?

Businesses and charities or third-sector organisations that are not approved UKRI independent research organisations cannot lead or co-lead, but they may participate as UK project partners. Approved UKRI independent research organisations have an exception described on the official page.

Do I submit a full proposal by 20 October 2026?

No. That is the deadline for the mandatory EOI. The full stage is scheduled for 5 November 2026 to 20 January 2027 and is open only to invitees.

Are matched funds required?

No institutional matched funding is required. Appropriate facilities and host support still need to be available for the research, and partner contributions can add value.

Where can I ask a question?

For opportunity-specific questions, MRC lists [email protected]. For costings and application-writing support, contact your research office first. The UKRI Funding Service helpdesk handles technical or account issues.

Start with the official UKRI opportunity page. It links to the mandatory EOI survey and records the current scope, eligibility rules, cost restrictions and application timeline. Use the survey linked from that page for the EOI; use the Funding Service only for the later full application if invited. Recheck the official page before submission in case MRC updates the instructions.

The immediate next step for an eligible UK research team is to confirm the lead and partner roles, contact the institutional research office, and submit a focused EOI before 20 October 2026 at 4:00pm UK time. In parallel, prepare the evidence and delivery plan needed for a possible full proposal, while waiting for the invitation and the full-stage guidance. The programme is competitive and the call does not guarantee that every EOI will be invited or that an invited application will receive funding.

Next step
Check official source